Salvia Compound Reshapes Gut Bacteria to Calm Artery Plaque Inflammation

Atherosclerosis kills more people worldwide than almost any other condition, yet the drugs that slow it mostly target cholesterol. A new mouse study published in June 2026 suggests a different lever worth watching: the trillions of bacteria living in the gut. Researchers found that lithospermic acid (LA), a polyphenol extracted from the herb Salvia miltiorrhiza, appears to remodel gut microbial communities in ways that dampen inflammation inside arterial plaques. The finding is early and animal-only, but it sketches a plausible biological pathway that could eventually inform new treatment strategies.

Lithospermic Acid Reduces Plaque Area in Two Mouse Models

Wu and colleagues tested LA in two genetically distinct mouse models of atherosclerosis: Apolipoprotein E knockout (ApoE-KO) mice and low-density lipoprotein receptor knockout (LDLR-KO) mice, both fed a Western diet. Mice received either 4 or 8 mg per kilogram per day of LA for 12 weeks. In both models, LA treatment significantly reduced atherosclerotic plaque development, increased collagen content within plaques (a marker of plaque stability), suppressed the pro-inflammatory cytokine TNFα, and raised levels of CD206, a surface marker associated with anti-inflammatory macrophages. LA also promoted macrophage efferocytosis, the process by which immune cells clear away dead and dying cells from plaque tissue. Together, these changes point toward a less inflamed, more structurally stable lesion.

To verify that the gut microbiome was responsible rather than LA acting directly on artery tissue, the team performed fecal microbiota transplantation (FMT) experiments. Recipient mice were first depleted of their own gut bacteria using antibiotics, then colonized with fecal material from either LA-treated or vehicle-treated donor mice. Recipients that received microbiota from LA-treated donors showed reduced plaque burden, mirroring the original LA results. This FMT evidence is central to the paper's argument that the gut microbiota influences plaque formation in a meaningful, transferable way.

Why Plaque Inflammation Is the Right Target

Most cardiovascular risk scores focus on lipid levels, but the biological crisis inside an artery wall is fundamentally inflammatory. Plaques accumulate macrophages that engulf oxidized LDL cholesterol, become foam cells, and release cytokines that accelerate local tissue damage. When macrophages lose their ability to clear apoptotic cells efficiently, dead material builds up inside the lesion. Plaques that are low in collagen and high in inflammatory cells are the ones most likely to rupture and trigger a heart attack or stroke; intraplaque hemorrhage and plaque instability are among the clearest histological warning signs. LA's apparent ability to shift macrophages toward an anti-inflammatory phenotype while boosting efferocytosis addresses exactly this failure mode.

Limitations of targeting systemic biomarkers like high-sensitivity C-reactive protein have been well documented: they lack the specificity needed to predict individual cardiovascular events. Intervening at the level of gut bacteria, which interact directly with immune signaling, may offer a more targeted route to cooling intraplaque inflammation without the broad immunosuppression that worries clinicians.

How 16S Sequencing and Metabolomics Traced the Mechanism

The team used 16S rRNA gene sequencing to track shifts in microbial community composition and paired it with serum metabolomics to map downstream chemical changes. Principal coordinate analysis showed a clear separation between the microbial communities of LA-treated and control mice. The Simpson diversity index also differed significantly between groups. At the genus level, Roseburia and Eisenbergiella increased with LA treatment; both belong to the class Clostridia and were positively correlated with serum phosphatidylcholine (PC) and negatively correlated with lysophosphatidylcholine (LysoPC).

That metabolite distinction matters. LA treatment raised serum PC while lowering LysoPC, a bioactive lipid known to drive vascular inflammation. In cell culture experiments, LysoPC treatment pushed peritoneal macrophages toward a pro-inflammatory state: it increased uptake of oxidized LDL, elevated Tnfα, Il-1β, and Il-6 expression, and severely compromised phagocytosis of apoptotic Jurkat T cells. Serum LysoPC correlated inversely with anti-inflammatory macrophage proportion and collagen content in plaques, while serum PC showed the opposite pattern. This proposed gut microbiota-LysoPC-macrophage axis draws on integrating multi-omics in microbiome research, an approach that researchers increasingly argue is necessary to move from correlation to mechanism in microbiome science. Importantly, LA did not affect serum trimethylamine N-oxide levels, suggesting the benefit operates through this LysoPC pathway rather than the more commonly studied TMAO route.

Key Limitations Before Any Clinical Translation

The study has several constraints that temper enthusiasm. Each experimental group included only six mice, a modest sample size that limits statistical confidence. Only male mice were used, which means estrogen-related differences in either atherosclerosis progression or microbiome composition remain unexplored. The entire dataset comes from rodent models; whether LA remodels gut bacteria in humans at all, let alone in a way that translates to plaque biology, is unknown.

The mechanistic argument also rests heavily on correlative evidence. The paper identifies associations between specific bacterial genera, LysoPC levels, and plaque phenotype, but direct causal validation, such as FMT in germ-free mice or macrophage-specific LysoPC receptor knockout experiments, has not yet been done. The limitations of systemic inflammation markers in predicting cardiovascular risk are a reminder that promising biological associations do not automatically translate into clinically actionable tools.

What Comes Next for Roseburia, Eisenbergiella, and LA Research

The most tractable next steps involve mechanistic confirmation. Germ-free mouse experiments colonized with defined bacterial communities containing or lacking Roseburia and Eisenbergiella could establish whether these genera are sufficient to reproduce LA's metabolic and plaque effects. Identifying the specific enzymatic steps by which these bacteria regulate PC and LysoPC ratios would give researchers a molecular handle on the pathway.

Longer term, the work raises the question of whether LA or direct supplementation with Roseburia-family probiotics could be tested in early-phase human trials, particularly in patients with subclinical atherosclerosis who are not yet on standard lipid-lowering therapy. Salvia miltiorrhiza extracts already have a long history of use in traditional Chinese medicine, which may ease some safety concerns, but pharmacokinetic data on oral LA in humans remains sparse. For now, this research adds a well-characterized mechanistic hypothesis to the growing body of evidence linking gut microbiome composition to cardiovascular disease, with a specific lipid metabolite, LysoPC, emerging as a potentially measurable intermediate.

Evidence rating

INVESTIGATIONAL — 75/100

Caveats:

• All findings are from mouse models only (ApoE-knockout and LDLR-knockout mice); no human data exist yet.
• Sample sizes were small (n=6 per group), limiting statistical confidence.
• Only male mice were studied, so results may not apply to females.
• The proposed gut microbiota → LysoPC → macrophage causal chain is largely correlative; direct mechanistic validation is still lacking.
• Funding source was not disclosed by the authors.

Preclinical study using two atherosclerosis-prone mouse models (n=6 per group). Demonstrates associations between lithospermic acid treatment, gut microbiota composition shifts, reduced serum lysophosphatidylcholine, and attenuated plaque inflammation; fecal microbiota transplantation supports a contributory role for the gut microbiota, but direct mechanistic validation of the proposed pathway is absent. No human data exist, and findings have not been independently replicated.

References

1. Chenxia Wu, Tiantian Zheng, Shishi Huang, et al. (2026). Lithospermic acid-induced gut microbiota remodeling alleviates intraplaque inflammation. Phytomedicine. https://doi.org/10.1016/j.phymed.2026.158462
2. Impact of the gut microbiome on atherosclerosis – PMC – NIH. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10986794/
3. Atsushi Sakamoto, Kenichiro Suwa, Rika Kawakami, et al. (2023). Significance of Intra-plaque Hemorrhage for the Development of High-Risk Vulnerable Plaque: Current Understanding from Basic to Clinical Points of View. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241713298
4. Jiahuan Helen He, Hanwen Wang, Eric Qiu, Qibin Qi, Zheng Wang (2025). Gut Microbiota and Atherosclerosis: Integrative Multi-Omics and Mechanistic Insights. Current Atherosclerosis Reports. https://doi.org/10.1007/s11883-025-01371-2
5. Maxim E Annink, Jordan M Kraaijenhof, Cheyenne Y Y Beverloo, et al. (2024). Estimating inflammatory risk in atherosclerotic cardiovascular disease: plaque over plasma?. European Heart Journal – Cardiovascular Imaging. https://doi.org/10.1093/ehjci/jeae314